GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alivus Life Sciences ALIVUS.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

1,474.40

-0.42%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in INR, from our data supplier.

FY2026

Revenue

₹25.52bn

FY2019FY2026

Net income

₹5.64bn

FY2019FY2026

Free cash flow

₹2.59bn

FY2019FY2026

Shareholders' equity

₹33.32bn

FY2019FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue₹25.52bn₹23.72bn₹21.85bn₹20.48bn₹20.87bn₹18.61bn₹15.37bn₹8.86bn
Research and development—————₹2.9m——
Operating income₹7.57bn₹6.24bn₹6.22bn₹6.01bn₹5.79bn₹5.62bn₹4.44bn₹2.36bn
Net income₹5.64bn₹4.86bn₹4.71bn₹4.67bn₹4.19bn₹3.52bn₹3.13bn₹1.96bn
Diluted earnings per share45.8839.4938.3038.1134.0328.5725.5515.96

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets₹39.83bn₹34.11bn₹28.50bn₹27.02bn₹24.71bn₹19.97bn₹17.26bn₹14.75bn
Cash and short-term investments₹7.83bn₹5.49bn————₹100.0m₹20.6m
Total liabilities₹6.51bn₹5.94bn₹5.18bn₹5.64bn₹4.17bn₹12.44bn₹13.24bn₹13.87bn
Debt₹567.7m₹566.1m————₹210,000₹210,000
Shareholders' equity₹33.32bn₹28.17bn₹23.32bn₹21.38bn₹20.54bn₹7.53bn₹4.02bn₹881.3m
Shares outstanding123m123m123m123m123m123m123m123m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations₹5.66bn₹4.11bn₹4.14bn₹3.06bn₹5.98bn₹3.88bn₹1.95bn₹104.3m
Capital spending−₹3.07bn−₹1.66bn−₹1.29bn−₹1.63bn−₹1.32bn−₹679.9m−₹511.7m−₹93.3m
Free cash flow₹2.59bn₹2.45bn₹2.85bn₹1.43bn₹4.65bn₹3.20bn₹1.44bn₹11.1m
Dividends paid−₹613.4m—−₹2.76bn−₹3.86bn−₹1.29bn———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₹6.40bn₹6.89bn₹6.73bn₹5.88bn₹6.02bn₹6.02bn₹6.42bn₹5.07bn
Operating income₹1.91bn₹1.94bn₹2.12bn₹1.61bn₹1.55bn₹1.84bn₹1.75bn₹1.19bn
Net income₹1.60bn₹1.63bn₹1.50bn₹1.30bn₹1.22bn₹1.42bn₹1.37bn₹953.2m
Diluted earnings per share13.0113.2212.2210.579.8811.5411.147.75
Cash from operations———₹2.61bn—₹1.72bn——
Capital spending———−₹1.13bn—−₹805.0m——
Free cash flow———₹1.48bn—₹914.0m——
Total assets—₹39.83bn—₹36.38bn—₹34.11bn—₹30.85bn
Cash and short-term investments—₹7.83bn—₹6.53bn—₹5.49bn—₹5.30bn
Debt—₹79.8m—₹75.5m—₹56.5m—₹26.0m
Shareholders' equity—₹33.32bn—₹30.15bn—₹28.17bn—₹25.38bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue7.6%6.5%—
Operating income8.0%6.1%—
Net income6.5%9.9%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin28.0%28.4%28.6%—
Net margin21.3%21.7%21.0%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Price to earnings32.423.225.717.212.322.1
Price to sales7.24.85.53.92.54.2

Dividends and splits

Per share, in the currency the company pays

Paid for 1 years. Last went ex-dividend on 1 Sept 2026.

FY2027FY2026FY2024FY2023FY2022
Paid in the year5.005.0022.5031.5010.50

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.